Common and Individually Specific Chromosomal Characteristics

Total Page:16

File Type:pdf, Size:1020Kb

Common and Individually Specific Chromosomal Characteristics [CANCER RESEARCH 36, 398-404, February 1976] Common and Individually Specific Chromosomal Characteristics of Cultured Human Melanoma1 Peter B. McCulloch,2 Peter B. Dent, Paula R. Hayes, and Shuen-Kuei Liao Hamilton Clinic, Ontario Cancer Treatment and Research Foundation [P. B. M., P. B. D., P. R. H., S. K. L.], and Departments of Medicine [P. B. M., P. R. H.] and Pediatrics [P. B. D. , 5. K. L.J, McMaster University, Hamilton, Ontario, Canada SUMMARY any histological class of tumor. However, with the advent of individual chromosome identification, this whole area ne Since individual chromosomes can be accurately identi quires further study. fied by new banding techniques, atebnin fluorescence was used for chromosome analysis in six cell lines and two MATERIALS AND METHODS primary outgrowths derived from human malignant mela noma. Gross aneuploidy was seen in all specimens, but Eight different cultures obtained from human malignant each culture contained at least 1 distinctive marker chromo melanoma were studied. Their sources, individual chromo some specific for that cell line in 87 to 100% of metaphases. somal characteristics, and modal distribution of 50 meta One of the primary explants contained a marker that was phases from each culture are summarized in Table 1. demonstrable in fresh tissue and persisted through 2 weeks M-6 and 73-61 were primary explants established from of culture. The same marker was found in all metaphases metastatic malignant melanomas in our laboratory. The tis from 2 different metastases, but skin fibroblasts from the sue was minced and trypsinized. Some cultures were ob same patient had a normal chromosome complement. tamed from single cell suspensions, while others grew out No common marker for human melanoma was found, but from small fragments under glass coven slips. Samples from in 6 of the 8 cultures the most frequently found marker was these primary outgrowths were taken at various times for formed by a brightly banded chromatid addition. Relative cytogenetic studies. polysomy for Chromosome 7 was found in 7 of the 8 All 8 cultures were grown as monolayers in Eagle's mini cultures and, for Chromosome 22, in 5 of the 8 cultures. The mum essential medium with Hanks' balanced salt solution frequency of polysomy of Chromosomes 7 and 22 was signif containing 4 mM L-glutamine, 10 to 20% heat-inactivated icant at the 5% level. fetal calf serum, 100 @tgofstreptomycin sulfate per ml, and 50 units of penicillin G pen ml at 37°ina humidified atmos phene of 5% CO2in air. For chromosome analysis, Colcemid INTRODUCTION was added at a final concentration of 1.0 @g/ml2hr before harvesting. The cells were treated with 0.075 M KCI for 30 The utilization of specific staining techniques produces mm and fixed in methanol:acetic acid (3:1, v/v). The slides distinctive banding patterns that allow precise identification were flame dried and stained with 0.5% atebnin according to of individual human chromosomes (3). In the study of neo the method of Lin et a!. (10). The slides were scanned and plasms, these banding techniques disclose abnormalities metaphases were photographed with a Carl Zeiss fluones that were previously hidden by uniform staining. cent microscope using dark-field ilium ination. In our laboratory we have established and are maintaining From each culture, 45 to 55 metaphases were photo several melanoma cell lines to study patient-specific and graphed. Ten kanyotypes were made and the other 35 to 45 tumor-specific immunity (8). Since these lines show consid photographs were scanned for chromosome markers. enable morphological heterogeneity, these chromosome The total number of copies of each normal autosome was studies were undertaken to characterize the lines so that ascertained from the 10 karyotypes to detect any constant our immunological investigations can be performed on pure nullisomy on polysomy (Table 3). For statistical analyses the cultures from a defined origin. frequency of each autosome was ranked for each culture. Many chromosomal abnormalities have been recorded in The degree of polysomy of each autosome was then ana fresh and cultured human cancers, but, with the exception lyzed according to the formula: (rank total —mean rank) ÷ of the Philadelphia chromosome in chronic myelocytic Ieu S.D. (7, 16). Values greaten than 2.95 are significant at the kemia, no specific chnomosomal marker has been found for 5% level. RESULTS ‘Supported by grants from The Ontario Cancer Treatment and Research Foundation. This is Paper 2 of the series “CharacterizationofHuman Malig nant Melanoma Cell Lines,―bythe same authors. The marker chromosomes described for each line (Tables 2 To whom requests for reprints should be addressed, at Ontario Cancer 1 and 2) and shown in the karyotypes (Figs. 1 to 3) were Treatment and Research Foundation, Hamilton Clinic, 711 Concession Street, Hamilton, Ontario, Canada L8V 1C3. seen in oven 50% of the metaphases examined. Other Received August 21, 1974; accepted November 6, 1975. marker chromosomes did occur in each cell line but were 398 CANCER RESEARCH VOL. 36 Downloaded from cancerres.aacrjournals.org on October 1, 2021. © 1976 American Association for Cancer Research. Chromosomes in Human Melanoma Table 1 Summary of the lines and primary outgrowths studied fre Designa designa quency marker Modal chro- of modal (9k)M-1Dr.tionObtained fromOriginal tionSex of donorHighestchromosomeRangeofchromosomenos.Frequencymosome no. no. 60NewJ. Fogh,RPMI-5966Unknownmar 2, lp+36—10053 to 57 YorkM-2Dr. 20NewJ. Fogh,RPMI-4445Unknownmar 637—7557 40M-3Dr. York66 to 70 64DenverM-4Dr. G. Moore,RPMI-8342Male4q+33-9053 14Denver86G. Moore,RPMI-7272Femalellq+ , llq++38—10046 10M-5Dr. 48Denver.M-6OurG. Moore,RPMI-8322Male4q+33—10053 distributionM-7Dr. laboratoryCaCI 73-36Femaleip 50—152Random 30Houston73-61OurM. Romsdahl,LeCa Strl9-4Male2q+38—7266 laboratoryCaCI 73-61Male5q+38—10046 14 87 10 Table 2 Metaphases High-fre containing quency the marker Culture markers (%) Description of marker M-1(RPMI-5966) mar 2 97 del(3)(p21) with terminal pale staining band (p21) elon gated lp+ 92 Chromosome 1 with bright chromatid addition 12p+ 90 Chromosome 12 with bright chromatid addition mar 1 87 Large metacentnic, with atypical banding M-2 (RPMI-4445) mar 6 87 Resembleschromosome18but haselongated palestain ing p arms mar 5 82 Large acrocentric, with banding unlike any human chro mosome mar 4 78 Large metacentric with atypical banding (differs from mar 1) mar 3 76 q arm of Chromosome 1 with shortened atypical banding of p arm M-3 (RPMI-8342) 4q+ 100 Chromosome 4 with bright chromatid addition “mini―11 82 Typical banding of Chromosome 11 , but smaller in size; possibly an isochromosome of the short arms of Chro mosome 12 17q/lOq 30 C-group size, made up by the long arms of Chromosome 17 attached at the centromere to the long arms of Chromosome 10 M-4 (RPMI-7272) llq+ 66 Chromosome 11 with chromatid addition consisting of 1 bright band llq++ 68 Chromosome 11 with 2 bright bands on the chromatid addition M-5 (RPMI-8322) 4q+ 100 Sameas in M-3 “mini―11 58 Sameas in M-3 17q/lOq 70 Same as in M-3 M-6 (CaCI73-36) 1p— 100 del(1)(p22),chromosome1 with 2/3of p arm deleted M-7 (LeCa Str 19-4) 2q+ 100 Chromosome2 with chromatid addition mar 9 92 Large acrocentric (differs from mar 5 in M-2) lp+ 88 Chromosome 1 with chromatid addition (differs from lp+ in M-1) mar 7 86 Large submetacentric with atypical banding mar 8 83 Long arm of Chromosome 3 attached at the centromere to a pale-stainingshort arm of uncertain origin 73-61(CaCI73-61) 5q+ 100 Chromosome 5 with chromatid addition present in less than 30% of the metaphases and were there- nomenclature defined at the Paris Conference on Standard i fore not useful in distinguishing the culture from another. zation in Human Cytogenetics (1971) (12). Whenever the origin of the marker chromosome could be M-1 (RPMI-5966). This is a slightly melanotic line estab determined, the marker chromosome was described by the lished oven 10 years ago at Roswell Park Memorial Institute FEBRUARY 1976 399 Downloaded from cancerres.aacrjournals.org on October 1, 2021. © 1976 American Association for Cancer Research. P. B. McCullochetal. from a human malignant melanoma. Metaphases from the Two other common markers were found in 30 to 82% of 1st to the 4th passage in our laboratory were studied. It has the metaphases in both of these lines (Table 2). The kanyo a moderately sharp, hyperdiploid mode with 60% of the types from both of these cell lines showed polysomy for the metaphases examined ranging between 53 to 57 chromo normal Chromosomes 7 and 22 in the highest frequencies somes. Four different markers were seen in 87 to 97% of the (Table3). metaphases examined. They are specific for this cell line M-4 (RPMI-7272). This is an amelanotic cell line estab and are described in Table 2 and seen in Fig. 1. Polysomy lished from a female patient and maintained in continuous for the normal Chromosome 22 was most frequent in the 10 culture for approximately 2 years before our studies. The karyotypes from this line (Table 3). 4th and 5th passages in our laboratory were studied. The M-2 (RPMI-4445). This is an amelanotic line established chromosome number was bimodal with 1 peak at 46 and a over 10 years ago from a human malignant melanoma at 2nd peak at 86. All of the 50 metaphases examined from this Roswell Park Memorial Institute. Metaphases from the 2nd line contained an abnormal Chromosome 11 with either 1 on and 6th passages in our laboratory were studied. The chro 2 bright bands added to the lower arm (Fig.
Recommended publications
  • Clinical Outcome in Pediatric Patients with Philadelphia Chromosome
    cancers Article Clinical Outcome in Pediatric Patients with Philadelphia Chromosome Positive ALL Treated with Tyrosine Kinase Inhibitors Plus Chemotherapy—The Experience of a Polish Pediatric Leukemia and Lymphoma Study Group Joanna Zawitkowska 1,*, Monika Lejman 2 , Marcin Płonowski 3, Joanna Bulsa 4, Tomasz Szczepa ´nski 4 , Michał Romiszewski 5, Agnieszka Mizia-Malarz 6, Katarzyna Derwich 7, Gra˙zynaKarolczyk 8, Tomasz Ociepa 9, Magdalena Cwikli´ ´nska 10, Joanna Treli´nska 11, Joanna Owoc-Lempach 12, Ninela Irga-Jaworska 13, Anna Małecka 13, Katarzyna Machnik 14, Justyna Urba ´nska-Rakus 14, Radosław Chaber 15 , Jerzy Kowalczyk 1 and Wojciech Młynarski 11 1 Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-059 Lublin, Poland; [email protected] 2 Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-059 Lublin, Poland; [email protected] 3 Department of Pediatric Oncology, Hematology, Medical University of Bialystok, 15-089 Bialystok, Poland; [email protected] 4 Department of Pediatrics, Hematology and Oncology, Medical University of Silesia, 40-752 Katowice, Poland; [email protected] (J.B.); [email protected] (T.S.) 5 Department of Hematology and Pediatrics, Medical University of Warsaw, 02-091 Warsaw, Poland; [email protected] 6 Department of Pediatric Oncology, Hematology and Chemotherapy, Medical University of Silesia, 40-752 Katowice, Poland; [email protected] 7 Department of Pediatric Oncology, Hematology and
    [Show full text]
  • Philadelphia Chromosome Unmasked As a Secondary Genetic Change in Acute Myeloid Leukemia on Imatinib Treatment
    Letters to the Editor 2050 The ELL/MLLT1 dual-color assay described herein entails 3Department of Cytogenetics, City of Hope National Medical Center, Duarte, CA, USA and co-hybridization of probes for the ELL and MLLT1 gene regions, 4 each labeled in a different fluorochrome to allow differentiation Cytogenetics Laboratory, Seattle Cancer Care Alliance, between genes involved in 11q;19p chromosome translocations Seattle, WA, USA E-mail: [email protected] in interphase or metaphase cells. In t(11;19) acute leukemia cases, gain of a signal easily pinpoints the specific translocation breakpoint to either 19p13.1 or 19p13.3 and 11q23. In the References re-evaluation of our own cases in light of the FISH data, the 19p breakpoints were re-assigned in two patients, underscoring a 1 Harrison CJ, Mazzullo H, Cheung KL, Gerrard G, Jalali GR, Mehta A certain degree of difficulty in determining the precise 19p et al. Cytogenetic of multiple myeloma: interpretation of fluorescence in situ hybridization results. Br J Haematol 2003; 120: 944–952. breakpoint in acute leukemia specimens in the context of a 2 Thirman MJ, Levitan DA, Kobayashi H, Simon MC, Rowley JD. clinical cytogenetics laboratory. Furthermore, we speculate that Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) the ELL/MLLT1 probe set should detect other 19p translocations in acute myeloid leukemia. Proc Natl Acad Sci 1994; 91: 12110– that involve these genes with partners other than MLL. Accurate 12114. molecular classification of leukemia is becoming more im- 3 Tkachuk DC, Kohler S, Cleary ML.
    [Show full text]
  • Trisomy 21 with a Small Supernumerary Marker Chromosome Derived From
    BJMG 13 (1) (2010) 10.2478/v10034-010-0020-x SHORT COMMUNICATION TRISOMY 21 WITH A SMALL SUPERNUMERARY MARKER CHROMOSOME DERIVED FROM CHROMOSOMES 13/21 AND 18 Niksic SB1, Deretic VI2, Pilic GR1, Ewers E3, Merkas M3, Ziegler M3, Liehr T3,* *Corresponding Author: Thomas Liehr, Institut für Humangenetik, Postfach, D-07740 Jena, Germany; Tel.: +49-3641-935-533; Fax: +49-3641-935-582; E-mail: [email protected] ABSTRACT influenced by maternal age and affected fetuses are at an increased risk of miscarriage [1]. Different theories We describe a trisomy 21 with a small are discussed how free trisomy 21 develops during supernumerary marker chromosome (sSMC) maternal meiosis [2,3]. In 35 reported DS cases instead derived from chromosomes 13/21 and 18 in which of a karyotype 47,XN,+21 there was a karyotype the karyotype was 48,XY,+der(13 or 21)t(13 48,XN,+21,+mar, i.e., a small supernumerary or 21;18)(13 or 21pter→13q11 or 21q11.1::18p marker chromosome (sSMC) was also present [4]. 11.21→18pter),+21. Of the 35 case reports in the The sSMC are a morphologically heterogeneous literature for a karyotype 48,XN,+21,+mar, in group of structurally abnormal chromosomes only 12 was the origin of the sSMC determined by which may represent different types of inverted fluorescence in situ hybridization (FISH), and only duplicated chromosomes, minute chromosomes one was a der(13 or 21) and none were derived and ring chromosomes. They can be characterized from two chromosomes. The influence of the partial unambiguously by molecular cytogenetics and are trisomy 18p on the clinical outcome was hard to usually equal in size or smaller than a chromosome determine, however, there are reports on clinically 20 in the same metaphase spread.
    [Show full text]
  • Derived from Chromosome 22, a Case Report
    1802 Case Report Hypogonadotropic hypogonadism associated with another small supernumerary marker chromosome (sSMC) derived from chromosome 22, a case report Abdullah1#, Cui Li2#, Minggang Zhao2, Xiang Wang2, Xu Li2, Junping Xing1 1Department of Urology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China; 2Centre for Translational Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China #These authors contributed equally to this work. Correspondence to: Junping Xing. Department of Urology, School of Medicine, The First Affiliated Hospital, Xi’an Jiaotong University, Xi’an 710061, China. Email: [email protected]. Abstract: The idiopathic hypogonadotropic hypogonadism (IHH) is portrayed as missing or fragmented pubescence, cryptorchidism, small penis, and infertility. Clinically it is characterized by the low level of sex steroids and gonadotropins, normal radiographic findings of the hypothalamic-pituitary areas, and normal baseline and reserve testing of the rest of the hypothalamic-pituitary axes. Delay puberty and infertility result from an abnormal pattern of episodic GnRH secretion. Mutation in a wide range of genes can clarify ~40% of the reasons for IHH, with the majority remaining hereditarily uncharacterized. New and innovative molecular tools enhance our understanding of the molecular controls underlying pubertal development. In this report, we aim to present a 26-year-old male of IHH associated with a small supernumerary marker chromosome (sSMC) that originated from chromosome 22. The G-banding analysis revealed a karyotype of 47,XY,+mar. High-throughput DNA sequencing identified an 8.54 Mb duplication of 22q11.1-q11.23 encompassing all the region of 22q11 duplication syndrome. Pedigree analysis showed that his mother has carried a balanced reciprocal translocation between Chromosomes 22 and X[t(X;22)].
    [Show full text]
  • First Case Report of Maternal Mosaic Tetrasomy 9P Incidentally Detected on Non-Invasive Prenatal Testing
    G C A T T A C G G C A T genes Article First Case Report of Maternal Mosaic Tetrasomy 9p Incidentally Detected on Non-Invasive Prenatal Testing Wendy Shu 1,*, Shirley S. W. Cheng 2 , Shuwen Xue 3, Lin Wai Chan 1, Sung Inda Soong 4, Anita Sik Yau Kan 5 , Sunny Wai Hung Cheung 6 and Kwong Wai Choy 3,* 1 Department of Obstetrics and Gynaecology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong, China; [email protected] 2 Clinical Genetic Service, Hong Hong Children Hospital, Ngau Tau Kok, Hong Kong, China; [email protected] 3 Department of Obstetrics and Gynaecology, Chinese University of Hong Kong, Hong Kong, China; [email protected] 4 Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong, China; [email protected] 5 Prenatal Diagnostic Laboratory, Tsan Yuk Hospital, Sai Ying Pun, Hong Kong, China; [email protected] 6 NIPT Department, NGS Lab, Xcelom Limited, Hong Kong, China; [email protected] * Correspondence: [email protected] (W.S.); [email protected] (K.W.C.); Tel.: +852-25-957-359 (W.S.); +852-35-053-099 (K.W.C.) Abstract: Tetrasomy 9p (ORPHA:3390) is a rare syndrome, hallmarked by growth retardation; psychomotor delay; mild to moderate intellectual disability; and a spectrum of skeletal, cardiac, renal and urogenital defects. Here we present a Chinese female with good past health who conceived her pregnancy naturally. Non-invasive prenatal testing (NIPT) showed multiple chromosomal aberrations were consistently detected in two sampling times, which included elevation in DNA from Citation: Shu, W.; Cheng, S.S.W.; chromosome 9p.
    [Show full text]
  • Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    Acute lymphoblastic leukemia Treatment of Philadelphia chromosome positive acute lymphoblastic leukemia O.G. Ottmann ABSTRACT Patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) are now Department of Internal Medicine, routinely treated front-line with tyrosine kinase inhibitors (TKI), usually combined with chemotherapy, Hematology-Oncology, with unequivocal evidence of clinical benefit. The first-generation TKI imatinib induces hematologic Goethe University, Frankfurt am remissions in nearly all patients, but these are rarely maintained unless patients undergo allogeneic Main, Germany stem cell transplantation (alloSCT), the current gold standard of curative therapy. The more potent sec - ond- and third-generation TKI display greater clinical efficacy based on molecular response data and Correspondence: clinical outcome parameters. It is still uncertain whether they may obviate the need for alloSCT in Oliver G. Ottmann some adult patients who achieve a deep molecular response, whereas this appears to often be the case E-mail: [email protected] in pediatric patients. Which chemotherapy regimen is best suited in combination with the individual TKI in different subsets of patients is being explored in ongoing studies. Molecular analyses to measure MRD levels, detect BCR-ABL kinase domain mutations, or further subclassify patients according to Hematology Education: additional genomic aberrations has become increasingly important in clinical patient management. A the education program for the variety
    [Show full text]
  • Acute Myeloid Leukemia with Both Meakaryoblastic & Basophilic
    Hematology & Transfusion International Journal Case Report Open Access Acute myeloid leukemia with both meakaryoblastic & basophilic differentiation Abstract Volume 5 Issue 2 - 2017 Acute myeloid leukemia with Megakaryoblastic and Basophilic differentiation and Mariam Al Ghazal, Mohammed Dastagir AH CML with concurrent Megakaryoblastic and Basophilic Blast crisis are very rare diseases with only few reported cases in the literature. Diagnosis of this leukemia with Khan Department of Hematopathology and Cytogenetic, Dammam two types of blasts of the same lineage can be very challenging and morphology alone regional laboratory, Saudi Arabia is not sufficient especially when the morphology is not classical. Flowcytometry and cytogenetic studies are important to establish the diagnosis. Here we report a case Correspondence: Mariam Al Ghazal, Department of of AML with Megakaryoblastic & basophilic differentiation & Positive Philadelphia Hematopathology and Cytogenetic, Dammam regional chromosome by FISH. laboratory, Saudi Arabia, Email [email protected] Keywords: leukemia, megakaryoblastic, basophilic, blast crisis, diagnosis Received: August 01, 2017 | Published: August 30, 2017 Abbreviations: AMLs, acute myeloid leukemias; CML, published case of similar morphological combination but negative for chronic myelogenous leukemia ph chromosome was published by Sreedharanunni et al.4 Introduction Case presentation Basophilia is commonly associated with Chronic Myelogenous A 54-year-old Egyptian man, who presented with Anemia and Leukemia, notably in the accelerated phase or during blast crisis. It lytic lesion as evident by x-ray, was referred to our institution for is also associated with other myeloproliferative neoplasms. However, Flowcytometry. Peripheral Blood shows WBC 1717×/ul. Hb- 6.7g/dl its association with acute leukemia is very rare and is described and Platelets count 82,000/ul.
    [Show full text]
  • PZ003 Bosutinib Pregnancy Mpls Layout Tc06
    Please note that this summary only contains information from the full scientific article: https://www.futuremedicine.com/doi/10.2217/ijh-2020-0004View Scientific Article Pregnancy outcomes in people who took bosutinib Date of summary: May 2020 Analysis end date: February 28, 2018 The full title of this article: Pregnancy outcomes in patients treated with bosutinib This study drug is approved to treat the condition This analysis reports the results of a number of studies. under study that is discussed in this analysis. The results of this analysis might be dierent from the results of other studies that the researchers look at. Researchers must look at the results of many types of studies to understand whether a study drug More information can be found in the scientific article of this works, how it works, and whether it is safe to analysis, which you can access here: https://www.futuremedicine.com/doi/10.2217/ijh-2020-0004View Scientific Article prescribe to patients Bosutinib <boh-SOO-tih-nib> Imatinib <ih-MA-tih-nib> Dasatinib <da-SA-tih-nib> Nilotinib <ny-LOH-tih-nib> Chronic myeloid leukemia Tyrosine kinase inhibitor < KRAH-nik MY-eh-loyd loo-KEE-mee-ah> <TY-ruh-seen KY-nays in-HIH-bih-ter> What did this analysis look at? • Chronic myeloid leukemia (CML for short) is a type of cancer that aects white blood cells. It tends to progress slowly over many years. – CML is caused by the formation of a gene called BCR-ABL, which causes the cancer cells to increase in number. – Genes are segments of DNA* and are found in structures called chromosomes within each cell of the body.
    [Show full text]
  • Chromosome Translocations and Human Cancer1
    [CANCER RESEARCH 46, 6019-6023, December 1986] Perspectives in Cancer Research Chromosome Translocations and Human Cancer1 Carlo M. Croce2 The Wistar Institute, Philadelphia, Pennsylvania 19104 The cytogenetic analysis of human cancer cells by standard rearrangement, somatic cell hybrids between mouse myeloma and by high resolution banding techniques indicates that more cells and Burkitt's lymphoma cells with the t(8; 14) chromosome than 90% of human malignancies carry clonal cytogenetic translocation were produced and analyzed with probes specific changes (1). The discovery of the Philadelphia chromosome in for the genes for the variable and constant regions of the human the neoplastic cells of patients with CML3 (2) and the subse heavy chains (13). The results of this analysis indicated that the quent findings that the great majority of human hematopoietic human heavy chain locus is split at various sites by the chro malignancies carry specific chromosomal alterations (3, 4) have mosomal translocation and that the genes for the variable suggested that such nonrandom chromosomal changes may be regions translocate to the involved chromosome 8 (8q-), while involved in the pathogenesis of human malignancies. This view, the genes for the constant regions remain on the involved however, was not shared by many investigators outside the field chromosome 14 (14q+) (13). Analysis of the hybrids for the of cancer cytogenetics, who regarded such chromosomal alter expression of human heavy chains also indicated that the ex ations as epiphenomena of the neoplastic process. pressed human heavy chain locus in Burkitt's lymphoma resides Recent developments in the analyses of genes involved in the on the normal chromosome 14 (13).
    [Show full text]
  • Philadelphia-Positive Acute Myeloblastic Leukemia: a Rare Entity Definition Genetics Mechanism Epidemiology Clinical Features Im
    Commentary iMedPub Journals Journal of Neoplasm 2016 http://www.imedpub.com/ ISSN 2576-3903 Vol.1 No.1:2 DOI: 10.217672576-3903.100002 Philadelphia-Positive Acute Myeloblastic Leukemia: A Rare Entity Smeeta Gajendra1 and Sahoo MK2 1Department of Pathology and Laboratory Medicine, Gurgaon, Haryana, India 2Department of Nuclear Medicine, All India Institute of Medical Science, New Delhi, India Corresponding author: Smeeta Gajendra, Associate Consultant, Department of Pathology and Laboratory Medicine, Medanta-The Medicity, Sector - 38, Gurgaon, Haryana 122 001, India, Tel: 09013590875, Fax: +91- 124 4834 111; E-mail: [email protected] Received date: March 13, 2016; Accepted date: April 06, 2016; Published date: April 12, 2016 Citation: Gajendra S, Sahoo MK. Philadelphia-Positive Acute Myeloblastic Leukemia: A Rare Entity. J Neoplasm 2016, 1:1 Definition transformation. In the ABL portion, these domains are the SH1 (tyrosine kinase), SH2 and actin-binding domains and in the Philadelphia positive (Ph+) Acute Myeloblastic Leukemia BCR portion, they are the coiled-coil oligomerization domain (AML) is an acute onset neoplasm of myeloblasts in which the comprised between amino acids (aa) 1-63, the tyrosine at blasts harbor BCR/ABL translocation in the absence of a clinical position 177 (GRB-2 binding site) and the phosphor serine/ history of chronic phase or accelerated phase chronic myeloid threonine rich SH2 binding domain. The increased tyrosine leukemia (CML) and a lack of clinical and laboratory features of kinase activity of BCR-ABL fusion protein results in CML, such as splenomegaly and basophilia. phosphorylation of several cellular substrates and auto- phosphorylation of BCR-ABL, which in turn induces Keywords: Philadelphia chromosome; BCR/ABL; Acute recruitment and binding of a number of adaptor molecules myeloid leukemia and proteins.
    [Show full text]
  • Presence of Harmless Small Supernumerary Marker Chromosomes Hampers Molecular Genetic Diagnosis: a Case Report
    MOLECULAR MEDICINE REPORTS 3: 571-574, 2010 Presence of harmless small supernumerary marker chromosomes hampers molecular genetic diagnosis: a case report HEIKE NELLE1,2, ISOLDE SCHREYER1,3, ELISABETH EWERS1, KRISTIN MRASEK1, NADEZDA KOSYAKOVA1, MARTINA MERKAS1,6, AHMED BASHEER HAMID1, RAIMUND FAHSOLD4, ANIKÓ UJFALUSI7, JASEN ANDERSON8, NIKOLAI RUBTSOV9, ALMA KÜCHLER5, FERDINAND VON EGGELING1, JULIA HENTSCHEL1, ANJA WEISE1 and THOMAS LIEHR1 1Institute of Human Genetics and Anthropology; 2Clinic for Children and Juvenile Medicine, Jena University Hospital, 07740 Jena; 3Center for Ambulant Medicine - Jena University Hospital gGmbH, Practice for Human Genetics, 07743 Jena; 4Middle German Practice Group, 01067 Dresden; 5Institute of Human Genetics, 45122 Essen, Germany; 6School of Medicine Zagreb University, Croatian Institute for Brain Research, 1000 Zagreb, Croatia; 7University of Medical and Health Science Center, Department of Pediatrics, Genetic Laboratory, Debrecen 4032, Hungary; 8Department of Cytogenetics, Sullivan Nicolaides Pathology, Taringa QLD, Australia; 9SA of RAderW, Institute of Cytologie and Genetics, 630090 Novosibrisk, Russian Federation Received April 7, 2010; Accepted May 25, 2010 DOI: 10.3892/mmr_00000299 Abstract. Mental retardation is correlated in approximately chromosomes, minute chromosomes and ring chromosomes. 0.4% of cases with the presence of a small supernumerary sSMC can only be characterized unambiguously by molecular marker chromosome (sSMC). However, here we report a (cyto)genetics and are equal in size or smaller than a chromo- case of a carrier of a heterochromatic harmless sSMC with some 20 of the same metaphase spread (1). The phenotypes fragile X syndrome (Fra X). In approximately 2% of sSMC associated with the presence of an sSMC vary from normal to cases, similar heterochromatic sSMC were observed in a clini- severely abnormal (2).
    [Show full text]
  • Secondary Philadelphia Chromosome Acquired During Therapy of Acute Leukemia and Myelodysplastic Syndrome
    Modern Pathology (2018) 31:1141–1154 https://doi.org/10.1038/s41379-018-0014-x ARTICLE Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome 1 1 2 1 2 Habibe Kurt ● Lan Zheng ● Hagop M. Kantarjian ● Guilin Tang ● Farhad Ravandi-Kashani ● 2 1 1 1 1 3 Guillermo Garcia-Manero ● Zimu Gong ● Hesham M. Amin ● Sergej N. Konoplev ● Mark J. Routbort ● Xin Han ● 1 1 1 Wei Wang ● L. Jeffery Medeiros ● Shimin Hu Received: 3 October 2017 / Revised: 29 November 2017 / Accepted: 3 December 2017 / Published online: 14 February 2018 © United States & Canadian Academy of Pathology 2018 Abstract The Philadelphia chromosome resulting from t(9;22)(q34;q11.2) or its variants is a defining event in chronic myeloid leukemia. It is also observed in several types of de novo acute leukemia, commonly in B lymphoblastic leukemia, and rarely in acute myeloid leukemia, acute leukemia of ambiguous lineage, and T lymphoblastic leukemia. Acquisition of the Philadelphia chromosome during therapy of acute leukemia and myelodysplastic syndrome is rare. We reported 19 patients, including 11 men and 8 women with a median age of 53 years at initial diagnosis. The diagnoses at initial presentation were = = = 1234567890();,: acute myeloid leukemia (n 11), myelodysplastic syndrome (n 5), B lymphoblastic leukemia (n 2), and T lymphoblastic leukemia (n = 1); no cases carried the Philadelphia chromosome. The Philadelphia chromosome was detected subsequently at relapse, or at refractory stage of acute leukemia or myelodysplastic syndrome. Of 14 patients evaluated for the BCR-ABL1 transcript subtype, 12 had the e1a2 transcript. In 11 of 14 patients, the diseases before and after emergence of the Philadelphia chromosome were clonally related by karyotype or shared gene mutations.
    [Show full text]